| Document |
Document Title |
|
WO/2009/139470A1 |
Disclosed is a pharmaceutical composition for the treatment of fibromyalgia, which comprises pilocarpine or a pharmacologically acceptable salt thereof. The pharmaceutical composition can be used as a novel therapeutic agent for fibromy...
|
|
WO/2009/139298A1 |
Disclosed is a metastin derivative represented by formula (I) (wherein the symbols are as defined in the description), a salt thereof, or a pharmaceutical composition containing the metastin derivative or a salt thereof. The metastin de...
|
|
WO/2009/133934A1 |
Disclosed are an agent for controlling labor pain and an agent for preventing or inhibiting premature birth, each of which comprises a protein incapable of passing through a placenta, particularly human placental leucineaminopeptidase (P...
|
|
WO/2009/133861A1 |
Disclosed is a cyclic amine compound useful as an androgen receptor modulator. [In formula (I), R1 represents a hydrogen atom, a halogen atom or the like; R2 represents a hydrogen atom, a halogen atom or the like; R3 represents a heteroc...
|
|
WO/2009/134713A1 |
The subject matter of the instant invention is pertinent to the field of male contraception. More specifically, the subject matter of the instant invention concerns methods of inhibiting spermatogenesis in males. The instant invention is...
|
|
WO/2009/134383A2 |
Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.
|
|
WO/2009/134718A1 |
The present invention relates to methods of administering compositions comprising a progesterone receptor antagonist for use in treating estrogen-dependent conditions. The invention is also directed to methods for treating pain associate...
|
|
WO/2009/134725A2 |
The subject matter of the instant invention is pertinent to the field of treatment of progesterone-dependent conditions. Compositions for practicing the methods, comprising one or more 19-norsteroid progesterone receptor modulators havin...
|
|
WO/2009/131096A1 |
Disclosed is a novel compound having NPY Y5 receptor antagonist activity, specifically a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or the salt. [In the formula, R1 repre...
|
|
WO/2009/131191A1 |
Disclosed is a stable metastin derivative having excellent biological activities (e.g., a cancer metastasis-inhibiting activity, a cancer proliferation-inhibiting activity, a gonadotropin secretion-promoting activity, a sex hormone secre...
|
|
WO/2009/131065A1 |
Disclosed is a compound useful as a prophylactic agent or a therapeutic agent for cardiovascular diseases, nervous system diseases, metabolic diseases, genital diseases, gastrointestinal diseases, neoplasm, infectious diseases and others...
|
|
WO/2009/128273A1 |
Provided is a method for potentiating the therapeutic effect of an iontophoresis preparation for treating breast cancer or mastitis. An iontophoresis preparation for treating breast cancer and/or mastitis which comprises a non-steroidal ...
|
|
WO/2009/129501A1 |
Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erecti...
|
|
WO/2009/128558A1 |
Disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof, which can be used as an activator for a PPAR. (In the formula, R1 and R2 independently represent a hydrogen atom, an alkyl group h...
|
|
WO/2009/128481A1 |
Disclosed is a glucokinase activator which is useful as a pharmaceutical agent such as a prophylactic/therapeutic agent for diabetes, obesity and others. Specifically disclosed is a compound represented by formula (I) [wherein each symbo...
|
|
WO/2009/128692A1 |
The invention relates to the development of a method and pharmaceutical compositions for obtaining plasmatic progesterone levels in humans and for maintaining a plasmatic progesterone concentration between 42 and 3.5 ng/mL for eight days...
|
|
WO/2009/124702A1 |
The invention relates to pharmaceutical compositions and forms of administration which contain compounds of general formula (I), and to contraceptive methods by administering these forms of administration. The invention further relates t...
|
|
WO/2009/123316A1 |
Disclosed is an sGC activator, particularly a compound which is useful for the prevention or treatment of diseases including hypertension, ischemic heart diseases, heart failure, kidney diseases, arteriosclerotic diseases, atrial fibrill...
|
|
WO/2009/121687A1 |
L-citrulline for treatment of endothelial dysfunction and in particular of erectile dysfunction and a pharmaceutical composition comprising L-citrulline in combination with one or more substances selected from the group consisting of pyc...
|
|
WO/2009/119534A1 |
Disclosed is a compound having an excellent DGAT inhibiting activity and an excellent anorexigenic activity or a pharmacologically acceptable salt thereof. Specifically disclosed is a compound represented by general formula (I) or a phar...
|
|
WO/2009/119726A1 |
Disclosed is an antagonist of a melanin-concentrating hormone receptor, which is useful as a medicinal agent for central nervous system diseases, cardiovascular diseases and metabolic diseases. Specifically disclosed is a diarylmethylami...
|
|
WO/2009/112678A2 |
The invention relates to the compounds of general formula (I) in which X1, X2, X3 and X4 are, independently of one another, a nitrogen atom or a C‑R1 group; Z1, Z2, Z3 and Z4 are, independently of one another, a nitrogen atom or a C‑...
|
|
WO/2009/114658A2 |
Provided are methods of inhibiting CYP17 in a mammal, such as a human, that include administering an effective amount of at least one CYP17 inhibitor, such as VN/124-1, VN/125-1, VN/85-1, VN/87-1 and/or VN/108-1 to the mammal. Also provi...
|
|
WO/2009/114757A2 |
A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, d...
|
|
WO/2009/111838A1 |
The present invention provides peptides and analogs and derivatives thereof having antimicrobial activity at least against Streptococcus uberis for the treatment of a range of infectious disease including mastitis, otitis externa, clostr...
|
|
WO/2009/110546A1 |
Provided is a composition containing as the active ingredient an extract of Ashwaganda leaves with pharmacological effects which has been extracted without using any organic solvents. Also provided is a method of producing the same. A co...
|
|
WO/2009/109710A1 |
The invention relates to compounds of the general formula (I) in which: G1, G2, G3 et G4 are independent from one another, a C-X group or a nitrogen atom; one of G1, G2, G3 and G4 and at most one of G1, G2, G3 and G4 is a C-X group In wh...
|
|
WO/2009/106531A1 |
The compounds of Formula (I) wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts...
|
|
WO/2009/104248A1 |
It is intended to find a substance having an action of effectively enhancing the production of adrenomedullin and to provide an adrenomedullin production enhancer using this substance. The adrenomedullin production enhancer is characteri...
|
|
WO/2009/103139A1 |
The present invention refers to a soap kit, preferably liquid, for women's intimate hygiene devised to take into consideration the different phases of the menstrual cycle, keeping the vaginal flora and helping to prevent infection. Besid...
|
|
WO/2009/101917A1 |
Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on a sodium channel and is therefore useful as a therapeutic agent for various types of neuralgi...
|
|
WO/2009/101789A1 |
Disclosed is an agent for improving the ovarian function, which can prevent the development of an ovarian function disorder by an anti-cancer chemical therapy to keep a fertilizing ability, has few adverse side effects, and can be admini...
|
|
WO/2009/099086A1 |
Disclosed is a compound which is useful as a prophylactic or therapeutic agent for cardiovascular diseases, nervous system diseases, metabolic diseases, genital diseases and gastrointestinal diseases. Specifically disclosed is a compound...
|
|
WO/2009/098283A1 |
The invention relates to 5,6 - dihydropyrrolo [2,1-a] isoquinoline and pyrrolo[2,1-a] isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of...
|
|
WO/2009/097709A1 |
The invention relates to the pharmaceutical technology field, especially relates to pyrazolopyrimidinone-containing phenyl guanidine derivatives represented by formula I, pharmaceutically acceptable salts or solvates thereof. The inventi...
|
|
WO/2009/099586A2 |
The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydroc...
|
|
WO/2009/095418A1 |
The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-l lβ-[4-JV, N-dimethylamino-phenyl)-19-norpregna- 4, 9-diene-3, 20-d...
|
|
WO/2009/095445A1 |
The present invention relates to use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for the treatment of impotentia generandi.
|
|
WO/2009/095437A1 |
The present invention pertains to the use of essential fatty acids for the preparation of a food composition for treating in particular post-surgical pain and/or pain due to a post- surgical relapse in women having undergone an operation...
|
|
WO/2009/091332A1 |
The invention relates to methods to be used in the maturation of ovarian follicles and oocytes. More specifically, the invention concerns the use of inhibitors of the phosphatase PTEN, such as oxovanadate and peroxovanadate complexes, in...
|
|
WO/2009/090202A1 |
The present invention relates to a monomaleate monohydrate salt of 7-methyl-6-{2-[4-(2- methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4,5-dihydroimidazo
[1,5-a]quinoline-3- carboxamide, uses of the salt as a medicament in the treatment of se...
|
|
WO/2009/048595A9 |
|
|
WO/2009/086634A1 |
Fertilized egg isolate, methods for preparing the fertilized egg isolate and uses thereof for treating mental health disorders and disease or conditions mediated by or associated with one or more glutamate receptors or by the neurokinin ...
|
|
WO/2009/088125A1 |
Disclosed are a composition for sanitary supplies for women (vaginal cleansing solution, vulval cleansing solution, vaginal tablet, etc.) comprising a mucosal immunoadjuvant and a preparation method thereof. Further disclosed are sanitar...
|
|
WO/2009/081789A1 |
A compound that is useful as an agent in the prevention and treatment of circulatory system, nervous system, metabolic, reproductive system, and gastrointestinal diseases. Formula (I) is a compound represented by the following: [structur...
|
|
WO/2009/079680A1 |
The application of wood material from a tree of the genus Larix for treatment and prophylaxis of inflammation in humans or animals is described. The present invention is based on the use of raw larch wood material as a medicament and an ...
|
|
WO/2009/077186A1 |
The present invention relates to nonsteriodal progesterone receptor modulators of the general formula 1, the use of the progesterone receptor modulators for producing medicaments and also pharmaceutical compositions containing these comp...
|
|
WO/2009/078432A1 |
Disclosed is a 1-alkyl-4-amino-1H-pyrazole-3-carboxamide compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is useful as a medicinal agent havin...
|
|
WO/2009/075334A1 |
The object aims to provide: a uterine fibroid cell growth inhibitor which is free from the risk of causing an adverse side effect including ovarian dysfunction and bone loss, and which can be administered over a long period; and a prophy...
|
|
WO/2009/074995A1 |
The present invention relates to chewable solid pharmaceutical compositions comprising sildenafil citrate. Sildenafil citrate is a very bitter drug, hence the conventional tablets, comprise of a film coating for aesthetic appearance and ...
|
